Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cerevel Therapeutics Hldg Inc (CERE)

Cerevel Therapeutics Hldg Inc (CERE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,530,120
  • Shares Outstanding, K 182,195
  • Annual Sales, $ 0 K
  • Annual Income, $ -432,840 K
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.44
Trade CERE with:

Options Overview Details

View History
  • Implied Volatility 30.27% ( -2.74%)
  • Historical Volatility 7.99%
  • IV Percentile 40%
  • IV Rank 27.21%
  • IV High 108.75% on 12/06/23
  • IV Low 0.94% on 12/29/23
  • Put/Call Vol Ratio 0.10
  • Today's Volume 23
  • Volume Avg (30-Day) 317
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 43,823
  • Open Int (30-Day) 47,437

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.58
  • Number of Estimates 6
  • High Estimate -0.43
  • Low Estimate -0.71
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.21 +0.29%
on 05/23/24
42.88 -3.61%
on 05/02/24
-0.57 (-1.36%)
since 04/24/24
3-Month
40.80 +1.30%
on 03/04/24
42.88 -3.61%
on 05/02/24
+0.45 (+1.10%)
since 02/23/24
52-Week
19.59 +110.97%
on 10/04/23
43.59 -5.18%
on 02/15/24
+8.24 (+24.90%)
since 05/24/23

Most Recent Stories

More News
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?

Revenue growth during what should be a disastrous patent cliff is encouraging.

CERE : 41.33 (-0.72%)
ABBV : 157.06 (-0.76%)
Is AbbVie Stock a Buy Now?

Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.

ABBV : 157.06 (-0.76%)
CERE : 41.33 (-0.72%)
Is AbbVie Stock a Buy Now?

The company is grappling with losing Humira's patent protection in 2023.

IMGN : 31.23 (unch)
CERE : 41.33 (-0.72%)
ABBV : 157.06 (-0.76%)
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December

These companies offer above-average income streams that should continue rising.

SRC : 42.31 (-1.56%)
CERE : 41.33 (-0.72%)
O : 52.18 (-0.25%)
BEPC : 32.37 (+2.63%)
BEP : 28.60 (+2.22%)
ABBV : 157.06 (-0.76%)
VZ : 39.74 (+0.79%)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?

The big drugmaker went on a holiday shopping spree.

AGN.AX : 0.765 (+8.51%)
ABBV : 157.06 (-0.76%)
IMGN : 31.23 (unch)
CERE : 41.33 (-0.72%)
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

ABBV : 157.06 (-0.76%)
CERE : 41.33 (-0.72%)
IMGN : 31.23 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 41.33 (-0.72%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 41.33 (-0.72%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 41.33 (-0.72%)
Why Shares of Cerevel Therapeutics Are Dropping Wednesday

The company reported second-quarter earnings.

CERE : 41.33 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics...

See More

Key Turning Points

3rd Resistance Point 41.76
2nd Resistance Point 41.66
1st Resistance Point 41.50
Last Price 41.33
1st Support Level 41.24
2nd Support Level 41.14
3rd Support Level 40.98

See More

52-Week High 43.59
Last Price 41.33
Fibonacci 61.8% 34.42
Fibonacci 50% 31.59
Fibonacci 38.2% 28.76
52-Week Low 19.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar